PROSTAGRAM – Image-based prostate cancer testing in the community

  • Research type

    Research Study

  • Full title

    PROSTAGRAM - Prostate Screening Trial using A Group of Radiological Approaches including MRI and ultrasound

  • IRAS ID

    247728

  • Contact name

    Hashim Ahmed

  • Contact email

    hashim.ahmed@imperial.ac.uk

  • Sponsor organisation

    Imperial College London

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    The purpose of this study is to test the feasibility of offering men, in the community, a health-check for prostate cancer based on imaging. The aim is to find an imaging technique, like mammograms for breast cancer, which could be used to test for prostate cancer.

    Prostate cancer mortality rates remain high, with 1-in-23 men dying from the disease (approximate 11,000 every year). For the first time, mortality rates have surpassed breast cancer. The NHS National Screening Committee has called for further research into new tests for prostate cancer.

    This trial is designed to test the feasibility of using well-established imaging techniques in men from the community aged 50-69 years. It will include:

    1. MRI – this uses magnetic signals to take detailed pictures of the prostate. It does not use radiation. Prostate MRI is used in men referred to hospital as it is able to identify areas of the prostate, which may contain significant cancer and allows a more precise targeted biopsy.

    2. Ultrasound (US) – this uses soundwaves to measure the stiffness of the prostate. It is more widely available than MRI and could be performed in the community more readily than MRI. It can also be performed in men that cannot have an MRI due to metal implants or claustrophobia.

    All men will have a PSA blood test (the standard-of-care test) as well as an MRI and US in a single visit (to reduce the burden of visits). Any suspicious areas on either imaging test will be biopsied. If men have a raised PSA blood test, they will also be advised to undergo a biopsy as that is the standard care approach. The positive test rate for each of the tests will be compared to judge whether it is feasible to carry out a subsequent larger more definitive trial.

  • REC name

    London - Camberwell St Giles Research Ethics Committee

  • REC reference

    18/LO/1338

  • Date of REC Opinion

    29 Aug 2018

  • REC opinion

    Favourable Opinion